Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine

Shahar Geva, Irena Lazarev, David Barry Geffen, Samuel Ariad

    Research output: Contribution to journalArticlepeer-review

    6 Scopus citations


    Several reports have described hypertriglyceridemia (HTG) in cancer patients, including breast cancer patients treated with capecitabine (CAP). However, the exact range of HTG in patients with metastatic breast cancer (MBC) treated with CAP has clearly not been defined. A retrospective analysis on 54 patients with MBC treated with CAP longer than 2 months was conducted. HTG was defined as triglyceride blood level above 150 mg/dl. Baseline data included age, body mass index (BMI), tumour characteristics, treatment duration, concomitant treatment with lapatinib, diagnosis of dyslipidemia, and diabetes mellitus, as well as antihyperlipidemic therapy. Clinically significant HTG (triglycerides >300 mg/dl) was found in 4/ 54 (7%) of patients. Post-treatment HTG was associated only with concomitant treatment with lapatinib (P<0.01). Three of the patients had dyslipidemia before treatment with CAP, and one patient also had diabetes-mellitus. No HTG-related complications occurred. Clinically significant HTG in MBC patients treated with CAP may be associated with pre-existing risk factors, such as dyslipidemia or diabetesmellitus.

    Original languageEnglish
    Pages (from-to)176-180
    Number of pages5
    JournalJournal of Chemotherapy
    Issue number3
    StatePublished - 1 Jun 2013


    • Breast cancer
    • Capecitabine
    • Diabetes mellitus
    • Hypertriglyceridemia
    • Lapatinib


    Dive into the research topics of 'Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine'. Together they form a unique fingerprint.

    Cite this